GHK-Cu: Side Effects & Safety

GHK-Cu (glycyl-L-histidyl-L-lysine combined with copper) is an endogenous tripeptide first isolated from human plasma in 1973. Plasma concentrations in healthy adults are roughly 200 ng/mL in the third decade of life and decline to ~80 ng/mL by age 60, which means most adults are exposed to GHK-Cu every day of their lives.^[1] This is the foundation of its strong safety record: the molecule is not foreign to human physiology.

Topical GHK-Cu has been used in commercial cosmetics for decades (Procyte's "Iamin" and Neutrogena's Visibly Firm line popularized it in the 1990s). Subcutaneous and intradermal use is a more recent and less-studied research application. The two routes have different side-effect profiles and we cover them separately below.

Note on legal status: GHK-Cu is not one of the seven peptides under FDA Pharmacy Compounding Advisory Committee (PCAC) review at the July 23–24, 2026 PCAC meeting (docket FDA-2025-N-6895). Topical GHK-Cu is widely sold as a cosmetic ingredient; injectable GHK-Cu sold for "research" purposes is not FDA-approved for human use. See our legal status guide for the broader regulatory picture.

The blue-green color comes from copper(II) coordinated with the GHK peptide. It is not a sign of irritation or toxicity — it's normal for the molecule. Higher concentrations show stronger color.

Injectable GHK-Cu has substantially less human safety data than topical use. The available literature is small and short-duration. Reported effects include:

• Injection-site reactions: redness, mild swelling, and bruising are the most commonly reported effects. Generally resolve within 24–72 hours.
• Transient flushing: facial flushing immediately after injection in a small subset of users, likely from histamine release; resolves within 30 minutes.
• Mild hypotension: single anecdotal reports; mechanism unclear; consider lower doses if you have baseline low blood pressure.
• Headache or mild fatigue: typically in the first week; commonly self-resolves.
• Sterile abscess: rare but possible with poor injection technique or contaminated reconstitution. See the injection technique guide.

No serious adverse events (hepatic, renal, cardiac, hematologic) have been reported in the published literature on therapeutic GHK-Cu dosing, but the sample sizes are very small.

Each GHK-Cu complex contains one Cu(II) ion. Standard topical use delivers negligible total copper. Subcutaneous protocols of 200–500 mcg daily deliver approximately 6–15 mcg of elemental copper per dose — well below the 900 mcg recommended daily allowance for adults and the 10,000 mcg/day upper limit set by the Institute of Medicine.^[3]

Despite the small dose, the following groups must avoid systemic GHK-Cu:

• Wilson's disease: an autosomal recessive disorder of copper metabolism (ATP7B mutation). Even small exogenous copper loads can worsen hepatic and neurological copper accumulation. Absolute contraindication.
• Indian childhood cirrhosis / idiopathic copper toxicosis: rare in adults; same principle applies.
• Active hepatic copper accumulation from any cause.
• Known copper allergy (e.g., patients who have reacted to copper IUDs).

If you have unexplained liver enzyme elevation, neurological symptoms, or a Kayser-Fleischer ring on eye exam, screen for Wilson's disease with serum ceruloplasmin and 24-hour urine copper before any copper-containing peptide.

Topical interactions

• Low-pH vitamin C (L-ascorbic acid): reduces copper(II) to copper(I) and breaks the complex. Use on alternate days or hours apart.
• Benzoyl peroxide: strong oxidizer; destroys the peptide. Separate by at least 30 minutes.
• Retinoids: not chemically incompatible but compounded irritation potential; introduce one at a time.
• AHAs / BHAs: low pH can affect stability; alternate days.

Systemic interactions

• Penicillamine, trientine, zinc acetate (Wilson's disease therapies): GHK-Cu opposes the therapeutic intent. Contraindicated.
• Other copper-containing supplements: account for total copper intake.
• No known interaction with cytochrome P450 substrates at typical research doses.

• Pregnancy: no controlled human pregnancy data exist. Copper crosses the placenta. Avoid systemic GHK-Cu during pregnancy. Topical cosmetic concentrations are likely low-risk but standard advice is to consult an obstetrician before using any active skincare ingredient.
• Breastfeeding: no lactation transfer data. Avoid systemic use.
• Children & adolescents: no pediatric safety data. Not recommended outside pediatric dermatology supervision.
• Active cancer: GHK-Cu modulates ~4,000 genes including some involved in angiogenesis and proliferation.^[2] Theoretically caution is warranted in active malignancy; discuss with oncology before use.

• Mild topical irritation: reduce to alternate-day application, drop concentration, or pause for 48 hours. Resume at lower frequency.
• Allergic skin reaction (rash, blistering, persistent erythema): stop immediately, treat with topical hydrocortisone if needed, see a dermatologist if symptoms persist beyond 72 hours.
• Persistent injection-site reaction beyond 5 days: evaluate for infection; consider sterile abscess. Stop and seek medical evaluation.
• Unexplained fatigue, abdominal pain, neurological symptoms during systemic use: stop and screen for copper accumulation (serum ceruloplasmin, 24-hour urine copper).

See the complete GHK-Cu guide, the dosage protocols, and the peptides for skin health overview.